CP3 Director Dr. Walid Gellad weighed in on the results of Lilly's new COVID-19 drug in BioPharma Dive. "Given the mechanism seems right and it's a big effect, I think the probability that it is real is high," said Dr. Gellad. "We obviously need more data, but for the criteria for an EUA, this seems like it should qualify."